IMMUNITYBIO, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K | $934.0K | $605.0K | $2.2M | $47.0K |
| Cost of Revenue | $753.0K | $0 | $0 | $0 | — | — | — | — |
| Gross Profit | $112.5M | $14.7M | $622.0K | $240.0K | — | — | — | — |
| Gross Margin | 99.3% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $190.1M | $232.4M | $248.1M | $196.0M | $139.5M | $112.0M | $55.7M |
| SG&A Expense | — | $168.8M | $129.6M | $102.7M | $135.3M | $71.3M | $46.5M | $42.7M |
| Operating Income | $-256.0M | $-344.2M | $-362.3M | $-351.3M | $-330.3M | $-220.9M | $-156.3M | $-98.4M |
| Operating Margin | -226.0% | -2,334.2% | -58,239.5% | -146,374.2% | -35,361.9% | -36,509.1% | -7,095.9% | -209,338.3% |
| Interest Expense | $60.9M | $114.6M | $128.8M | $63.5M | $14.8M | $9.1M | $5.9M | — |
| Pretax Income | $-351.6M | $-413.6M | $-583.9M | $-417.3M | $-349.8M | $-226.0M | $-160.3M | $-96.7M |
| Income Tax Expense | $-135.0K | $0 | $-40.0K | $34.0K | $9.0K | $-1.8M | $-105.0K | $-503.0K |
| Net Income | $-351.4M | $-413.6M | $-583.2M | $-416.6M | $-346.8M | $-221.9M | $-157.8M | $-96.2M |
| Net Margin | -310.2% | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% | -36,669.6% | -7,165.2% | -204,736.2% |
| EPS (Basic) | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | $-1.22 |
| EPS (Diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | $-1.22 |
| Shares Outstanding (Basic) | 919.9M | 697.3M | 508.6M | 399.9M | 389.2M | 377.1M | 366.3M | 79.1M |
| Shares Outstanding (Diluted) | 919.9M | 700.4M | 508.6M | 399.9M | 389.2M | 377.1M | 366.3M | 79.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |